SATIGREL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H19NO4
Molecular Weight	337.3692
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1)C(=C(CCC(O)=O)C#N)C2=CC=C(OC)C=C2

InChI

InChIKey=GRVCTHTXJDYIHB-UHFFFAOYSA-N

InChI=1S/C20H19NO4/c1-24-17-8-3-14(4-9-17)20(16(13-21)7-12-19(22)23)15-5-10-18(25-2)11-6-15/h3-6,8-11H,7,12H2,1-2H3,(H,22,23)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9063033 | https://www.ncbi.nlm.nih.gov/pubmed/7486235 | https://www.ncbi.nlm.nih.gov/pubmed/9122990 |https://adisinsight.springer.com/drugs/800000441

Satigrel (previously known as E5510) was developed as an antithrombotic agent. Satigrel antagonized platelet activation by inhibiting phospholipase C and/or A2, which results in suppression of both phosphatidylinositol breakdown and arachidonic acid release from phospholipids, as well as by inhibiting cyclooxygenase. Satigrel was studied in patients with intermittent claudication due to arteriosclerosis obliterans, where the drug improved the cutaneous circulation and symptoms of patients. In addition, the therapeutic effect of satigrel was studied on biopsy-proven chronic rejection after kidney transplantation. Also was shown that the drug had a clinical benefit over aspirin for the treatment of transient ischemic attacks. However, all these studied were apparently discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Satigrel, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts.	1998-01	9445241
A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group.	1995-11	7486235
Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid.	1987-10	3124862

Patents

Sample Use Guides

In Vivo Use Guide

After giving informed consent and one week wash-out of effected agents, a 2 mg oral dose of satigrel twice daily was administered for more than 4 weeks.

Route of Administration: Oral

Name

Type

Language

SATIGREL [MI]

Preferred Name

English

SATIGREL

Official Name

English

satigrel [INN]

Common Name

English

SATIGREL [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327